How to Read Anabolic Steroid Blood Test Markers That Matter

Roids Questions Team

What Blood Tests Show About Anabolic Steroid Use

If you are using, or considering using, anabolic-androgenic steroids (AAS), blood tests are the closest thing you have to an objective dashboard. They do not tell the whole story on their own, but they can show whether your cardiovascular, hormonal, liver, and kidney systems are responding in ways that deserve attention. The key is knowing which test does what, because a standard GP blood panel and a dedicated steroid screen are two very different tools.

How blood tests detect anabolic steroids: parent compounds vs. metabolites

When a steroid enters the body, it is rarely excreted unchanged. The liver, kidneys, and other tissues convert it into metabolites, some of which persist longer than the parent drug. This is why modern anti-doping and forensic tests do not only look for the original molecule. They look for both the parent compound and its known metabolites, often using gas or liquid chromatography paired with mass spectrometry.

Each steroid has a characteristic metabolic fingerprint. For example, nandrolone and its metabolites can be distinguished from testosterone-derived compounds. Some metabolites are only produced in tiny amounts, so laboratories use sensitive instrumentation to push detection windows back for days or weeks after the last dose. The exact window depends on the ester, route of administration, dose, and individual metabolism.

Testing methods: GC-MS and LC-MS as dedicated panels

Gas chromatography-mass spectrometry (GC-MS) and liquid chromatography-tandem mass spectrometry (LC-MS/MS) are the workhorses of dedicated steroid testing. GC-MS is robust for many non-polar steroids and metabolites, while LC-MS/MS handles compounds that break down under the heat of GC. Many accredited labs use both, depending on the target list. Current analytical approaches for detecting anabolic agents are summarized in PMC10962511.

These panels are not the same as the urine cups used for workplace drug screening. A standard five- or ten-panel workplace screen is designed for drugs of abuse such as opioids, cocaine, amphetamines, and cannabis. It will not reliably detect testosterone esters, nandrolone, trenbolone, or oral AAS. If a clinician or organization specifically wants to check for AAS, they must order a dedicated anabolic-steroid panel.

Why standard GP blood work often flags results as abnormal for users

Even though your GP is not running a steroid test, the routine metabolic panel can still return values that look unusual for someone using AAS. Total testosterone may be far above the reference range, or, if someone is suppressed, it may be unexpectedly low between cycles. Estradiol can climb due to aromatization. Hematocrit may rise because androgens stimulate erythropoiesis. HDL cholesterol often falls, especially with certain oral agents. Liver enzymes can increase with C-17 alpha-alkylated orals.

A GP who does not know the context may interpret these results as unexplained abnormalities and order more tests, sometimes leading to unnecessary anxiety or referrals. Bringing a clear timeline of any substances used, and knowing what markers to expect, makes the conversation far more productive.

Key Biomarkers to Monitor: Reading Your Results

Whether you are trying to establish a baseline or check in mid-cycle, the same core markers come up again and again. The table below shows what they represent and why they matter for someone exposed to exogenous androgens.

Marker	Typical reference range (adults)	Why it matters for AAS users
Total testosterone	Males: ~9–32 nmol/L (260–930 ng/dL); Females: ~0.3–2.4 nmol/L (9–70 ng/dL)	Shows endogenous production and exogenous supply; suppressed values off-cycle suggest hypogonadism.
Dihydrotestosterone (DHT)	Males: ~1.0–3.5 nmol/L; Females: ~0.1–0.6 nmol/L	A more potent androgen; high levels may correlate with androgenic side effects.
Estradiol	Males: ~40–160 pmol/L (11–44 pg/mL); Females: varies by cycle phase	Rises when testosterone aromatizes; very low or very high values can both cause symptoms.
FSH	Males: ~1.5–12.4 IU/L; Females: follicular ~3.5–12.5 IU/L	Pituitary signal for sperm production; suppressed on cycle, should recover afterward.
LH	Males: ~1.7–8.6 IU/L; Females: follicular ~2.4–12.6 IU/L	Pituitary signal for testosterone production; often near zero during AAS use.
Hematocrit	Males: ~38–50%; Females: ~35–47%	Androgens increase red blood cell mass; high values thicken blood and raise cardiovascular strain.
HDL cholesterol	Men: >1.0 mmol/L (40 mg/dL); Women: >1.3 mmol/L (50 mg/dL)	Often drops with AAS, particularly oral agents; low HDL is a cardiovascular concern.
LDL cholesterol	Ideally <3.0 mmol/L (<116 mg/dL)	May rise or shift unfavorably with some compounds; combined with low HDL it worsens lipid profile.
ALT	Males: ~10–55 U/L; Females: ~7–45 U/L	Liver enzyme; elevations common with oral C-17 alpha-alkylated steroids or heavy training.
AST	Males: ~15–40 U/L; Females: ~13–35 U/L	Liver/muscle enzyme; can rise after intense exercise, so ALT is usually more specific.
eGFR / creatinine	eGFR >90 mL/min/1.73m²; creatinine varies by muscle mass	Kidney function; high protein intake, dehydration, and some agents can affect readings.

Reference ranges differ between laboratories and populations, so always read your own report’s range rather than memorizing a single number. A result slightly outside the printed interval is not automatically dangerous, and a result inside the interval is not automatically harmless. Context is everything.

Hormone panel: testosterone, DHT, estradiol, FSH, LH baseline values

Before any exposure, you want to know where your natural axis sits. Testosterone, DHT, and estradiol give you a picture of circulating androgens and estrogenic activity. FSH and LH tell you whether your pituitary is signaling your testes or ovaries to produce hormones. If these are already borderline before a cycle, recovery may be harder, and that information is valuable when planning follow-up.

During a cycle with exogenous testosterone, total testosterone will obviously rise. The more useful number mid-cycle is often free testosterone, because sex-hormone-binding globulin (SHBG) can be suppressed by androgens, changing how much hormone is biologically active. Estradiol should be tracked because aromatization can produce estrogenic effects even when total testosterone looks fine. FSH and LH usually collapse toward the bottom of the range while exogenous hormones are present; if they do not recover weeks after cessation, that is a signal to involve a clinician.

Hematocrit levels and full blood count (FBC) thresholds for males and females

One of the most consistent effects of AAS is an increase in red blood cell production. For some users, hematocrit can climb several percentage points above their baseline. In males, values above 50–52% are often flagged; in females, values above 47–48% may attract attention. These thresholds are not universal, but they are commonly used as prompts to look closer.

A full blood count also reveals hemoglobin, red cell count, mean corpuscular volume, and platelets. A rising hematocrit without other abnormalities usually points to androgen-driven erythropoiesis, but dehydration or altitude can also raise it. Repeatedly high values, especially with symptoms such as headache, flushing, or fatigue, should prompt a conversation about therapeutic phlebotomy or dose adjustment.

Lipid panel: HDL/LDL changes and what normal ranges mean in context

Lipid shifts are common and can occur quickly. HDL cholesterol may fall within days to weeks of starting certain oral AAS, and LDL may rise or become more oxidized. The ratio between HDL and total cholesterol, or between HDL and LDL, is often more informative than any single number. A young, lean, training person may have a higher total cholesterol than a sedentary peer and still be in a very different metabolic state, so do not compare your numbers to population averages without considering training status and diet.

That said, a sustained HDL below 0.8 mmol/L (30 mg/dL) or an LDL/HDL ratio above 4–5 is generally considered unfavorable. These values are worth addressing through diet, cardio, omega-3 intake, and compound selection before they become entrenched.

Liver and kidney function markers: when results warrant attention

Oral C-17 alpha-alkylated steroids stress the liver by resisting first-pass metabolism. This can push ALT and AST above the reference range, sometimes several-fold. A mild rise after a heavy leg day or a new training block is usually benign, but a persistent, progressive rise, especially with symptoms such as itching, dark urine, pale stools, or right-upper-quadrant discomfort, needs medical evaluation.

Kidney markers are affected by hydration, protein intake, blood pressure, and some AAS. Creatinine can be high simply because you carry more muscle, so eGFR is usually more informative. If eGFR trends downward or creatinine rises while blood pressure climbs, that combination deserves attention. A simple repeat test after 48 hours of normal hydration can sometimes clarify whether the result is real or artifact.

Blood Work Timing: When and How Often to Test

Testing at the wrong time can hide more than it reveals. A single blood draw taken the morning after an injection, for example, may show sky-high testosterone that does not reflect the trough later in the week. The goal is to capture trends, not snapshots.

Pre-cycle baseline testing: what to establish before starting

At minimum, get a baseline four to eight weeks before any exposure. This should include a hormone panel, full blood count, lipid panel, liver enzymes, kidney function, and fasting glucose or HbA1c if metabolic health is a concern. Optional but valuable additions include SHBG, prolactin, thyroid-stimulating hormone (TSH), IGF-1, and PSA for males over 40 or those with prostate risk factors.

The baseline tells you what “normal” looks like for you. Without it, you will not know whether a mid-cycle value is a change from baseline or simply your natural tendency. This is especially important for hematocrit, HDL, and liver enzymes, all of which vary widely between individuals.

Testing intervals during a cycle: monitoring frequency recommendations

For most users, the practical minimum is one mid-cycle panel and one end-of-cycle panel. For longer or more complex cycles, testing every four to six weeks is more informative. The exact schedule depends on compounds, dose, and personal risk factors. Compounds that strongly affect lipids or hematocrit justify more frequent checks.

If you inject testosterone esters, try to draw blood at the same interval from your last injection each time—usually just before the next injection, at trough. This makes week-to-week comparisons meaningful. Random draws can create noise and lead to overreactions.

Post-cycle blood work: when to retest after cessation

After the last injection or tablet, the body needs time to clear exogenous hormones and restart its own production. A common approach is to test four to six weeks after the last long-ester injection, or two to three weeks after short-ester or oral compounds. If a post-cycle therapy (PCT) protocol is used, some people test immediately before PCT, mid-PCT, and again four to six weeks after PCT ends.

The markers that matter most post-cycle are total and free testosterone, estradiol, LH, FSH, and hematocrit. Lipids and liver enzymes often improve once the offending compound clears, but they should be confirmed with a repeat test. Full recovery can take months, so do not panic if values are not perfect at the first post-cycle draw.

Comprehensive Panels vs. Single Tests

It is tempting to order only testosterone and maybe hematocrit, but a narrow panel can give a false sense of security. AAS affect multiple organ systems simultaneously, and a problem in one area can be masked by a normal value in another.

Full steroid panel composition: 8+ tests covering 68+ biomarkers

A comprehensive sports pharmacology panel typically bundles at least eight test groups: a full blood count, hormone panel (testosterone, free testosterone, SHBG, estradiol, DHT, FSH, LH, prolactin), lipid panel, liver function panel, kidney function panel, thyroid panel, inflammatory markers, and metabolic markers such as fasting glucose and HbA1c. Some panels extend to IGF-1, PSA, and cortisol. In total, these can cover 60 to 80 individual biomarkers.

This breadth matters because changes are interconnected. Low HDL, high hematocrit, and rising blood pressure can all increase cardiovascular strain at the same time. A full panel lets you see the pattern rather than treating each marker in isolation. For a broader view of which compounds typically affect which markers, our guide to sports pharmacology compounds explains which drugs typically affect which markers.

Why partial testing misses critical markers

Testing only total testosterone and ALT, for example, would miss a falling HDL, a climbing hematocrit, or rising estradiol. Each of those can produce symptoms—fatigue, gynecomastia, water retention, headache, reduced cardiovascular capacity—before they show up as dramatic lab abnormalities. By the time a single marker looks alarming, several others may already be trending in the wrong direction.

Partial testing is also risky after a cycle. LH and FSH can be suppressed even when testosterone has partially recovered, which means the hypothalamic-pituitary-gonadal axis is not fully back online. Without those pituitary markers, you might assume recovery is complete when it is not.

IGF-1, PSA, and other specialized markers in complete assessment

IGF-1 reflects growth-hormone activity and can be useful if growth-hormone secretagogues or peptides are part of the protocol. It is not necessary for every AAS user, but it adds context when tissue growth, water retention, or insulin sensitivity are concerns.

Prostate-specific antigen (PSA) is primarily relevant for males, especially those over 40 or with a family history of prostate disease. Androgens can stimulate prostate tissue, so a baseline PSA and periodic follow-up are prudent. Other specialized markers—such as high-sensitivity C-reactive protein (hs-CRP), homocysteine, or ferritin—can be added based on personal history and the specific compounds used.

Reading Results in Context: Expected vs. Abnormal

Reference ranges are built from population averages, often drawn from sedentary adults. An athlete or regular trainee may naturally sit at the edge of, or just outside, these ranges for reasons that have nothing to do with AAS. The art is knowing when to relax and when to act.

Reference ranges for intensive athletes vs. sedentary population

Intensive resistance training tends to raise hematocrit, creatinine, and sometimes AST. It can lower HDL in some people, especially during high-volume blocks. These are adaptations, not necessarily diseases. A sedentary population reference range may label a fit trainee’s creatinine as “high” simply because they have more muscle mass.

On the other hand, some values should not be waved away. Hematocrit above 54% in males or 50% in females, HDL below 0.8 mmol/L (30 mg/dL), ALT more than three times the upper limit of normal, or eGFR trending below 60 are all signals that deserve a plan, not just a shrug about being an athlete.

How to distinguish between expected adaptations and concerning findings

The most reliable method is to compare against your own baseline. A 5% rise in hematocrit from your personal normal is very different from a value that jumps straight into the danger zone. Trends across multiple draws are more valuable than a single outlier. If a marker moves steadily in one direction over two or three tests, that is stronger evidence of a real change than one surprising result.

Symptoms matter too. A slightly elevated AST after a new training block is probably muscular if you have no other signs. A high ALT with fatigue, nausea, or jaundice is not. A high hematocrit with headaches and blurred vision carries more urgency than a high hematocrit with no symptoms. Use the lab numbers as one input among several.

When elevated hematocrit requires action or cycle adjustment

Hematocrit is one of the clearest examples of a marker that sits in a gray zone. Values around 50–52% in males may be a prompt to increase hydration, add regular cardio, and recheck soon. Values persistently above 54% in males, or above 50% in females, usually require a more active response. Options discussed in clinical settings include therapeutic phlebotomy, dose reduction, switching to a less erythropoietic compound, or pausing the cycle entirely.

How high is too high also depends on blood pressure, symptoms, and cardiovascular risk factors. A young, otherwise healthy person with hematocrit of 53% and no symptoms may simply be monitored closely, while an older person with hypertension and hematocrit of 52% may need quicker intervention. This is why a single number never tells the whole story.

Putting It All Together

Blood testing is not a substitute for medical care, but it is an indispensable tool for anyone navigating AAS use. The right panel, drawn at the right time, turns vague symptoms into trackable data. It helps you distinguish between normal adaptations, manageable shifts, and findings that need professional attention.

The most important habits are simple: establish a baseline, use the same lab where possible, draw at consistent times relative to injections, track trends rather than single values, and always share your results with a clinician who knows the full context. The goal is not to chase perfect numbers; it is to catch problems early while they are still easy to address.